Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24520149 | 1.00 | KMT2A (0.54) | KMT2AEPHX2EPHX1OPRD1 | |
| SCHEMBL10137494 | 0.99 | KMT2A (0.55) | KMT2AEPHX2EPHX1OPRD1 | |
| SCHEMBL30759497 | 0.96 | KMT2A (0.55) | KMT2AEPHX2OPRD1 | |
| SCHEMBL13020981 | 0.93 | KMT2A (0.57) | KMT2AEPHX2OPRD1 | |
| SCHEMBL6762266 | 0.87 | KMT2A (0.52) | KMT2AEPHX2 | |
| SCHEMBL23571459 | 0.87 | F2 (0.53) | KMT2AEPHX2OPRD1 | |
| SCHEMBL3046952 | 0.87 | KMT2A (0.56) | KMT2AEPHX2 | |
| SCHEMBL119618 | 0.86 | KMT2A (0.54) | KMT2AEPHX2OPRD1 | |
| SCHEMBL31693430 | 0.86 | KMT2A (0.54) | KMT2AEPHX2OPRD1 | |
| SCHEMBL30309102 | 0.86 | KMT2A (0.54) | KMT2AEPHX2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083209-A1 | LIGAND COMPOUND TARGETING PSMA ANTIGEN, AND CHELATE AND USE THEREOF IN DIAGNOSIS AND TREATMENT OF PROSTATE CANCER | 苏州瑞核医药科技有限公司 | 2023-05-19 | — | — | WO | disclosed |
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021530-A1 | HETEROGENEOUS FOLDAMERS CONTAINING alpha, beta, and/or gamma-AMINO ACIDS | DNPEP, PRKCSH, YWHAZ | KMT2A 3597/4885EPHX2 2808/4885EPHX1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.